loader image
Thursday, March 28, 2024
58.5 F
McAllen
We Welcome your Press Release
- Advertisement -

Lowering Prescription Drug Costs for Texans

Translate to Spanish or other 102 languages!

U.S. Senator John Cornyn (R-TX) discussed his bipartisan Affordable Prescriptions for Patients Act, which passed unanimously out of the Senate Judiciary Committee last Congress and would help lower drug prices. Image Source: United States Senate, Public domain, via Wikimedia Commons for illustration purposes
U.S. Senator John Cornyn (R-TX) discussed his bipartisan Affordable Prescriptions for Patients Act, which passed unanimously out of the Senate Judiciary Committee last Congress and would help lower drug prices. Image Source: United States Senate, Public domain, via Wikimedia Commons for illustration purposes

Mega Doctor News

- Advertisement -

WASHINGTON, DC – Today on the floor, U.S. Senator John Cornyn (R-TX) discussed his bipartisan Affordable Prescriptions for Patients Act, which passed unanimously out of the Senate Judiciary Committee last Congress and would help lower drug prices by preventing bad actors’ anti-competitive use of patents to block generic and biosimilar competition from coming to market. Excerpts of Sen. Cornyn’s remarks are below, and video can be found here

“The list price for Humira is more than $80,000 per year per patient. That’s higher than the median household income in Texas.”

“Humira is one of the most egregious examples of patent abuse, but it’s far from the only one.”

- Advertisement -

“Earlier this week Senator Blumenthal, the Senator from Connecticut, and I reintroduced a bill called the Affordable Prescriptions for Patients Act to put an end to this anti-competitive practice that keeps drug prices artificially high.”

“There are two practices in particular that this bill will address. One is called patent thicketing, which involves building layers upon layers of patents to prevent competitors from ever hitting the market. That’s what AbbVie did with Humira.”

“The other anticompetitive behavior this bill will address is something called product hopping, which occurs when a company develops a reformulation of a product that’s about to lose exclusivity, and then pulls the original product off the market. This is done not because the new formula is more effective, but because it prevents generic competitors.”

“The Affordable Prescriptions for Patients Act puts an end to this practice by expressly prohibiting manufacturers from engaging in product hopping. It also facilitates market entry for generics and biosimilars, which lead to more options and lower prices for patients.”

- Advertisement -

“Patients in Texas and across the country are experiencing sticker shock at the pharmacy counter like never before.”

“There’s a bipartisan desire to stop the anti-competitive behaviors that I described here today that are costing patients and taxpayers a fortune, and I hope we can make progress this Congress and finally put a stop to some of the gamesmanship.”

Senator John Cornyn, a Republican from Texas, is a member of the Senate Finance, Intelligence, and Judiciary Committees.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Experts Highlight Strategies for Cancer Control and Prevention

Make cancer screening part of your lifestyle

Sneaky Ways Sugar is Hidden in Some Food

So, how can you tell if sugar is hidden in a product?

Dr. Andrew W. Phillips and the Pioneering ECMO Program at DHR Health

In a year marked by significant medical advancements within the Rio Grande Valley, DHR Health's celebration of the first anniversary of its Extracorporeal Membrane Oxygenation (ECMO) program stands out as state-of-the-art innovation and hope.

DHR Health Physicians, First in Texas to Offer Innovative Patient-Centric Treatment for Urge Urinary Incontinence

UUI, also known as urgent bladder leaks, is a common and often embarrassing problem.
- Advertisement -
×